Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + paclitaxel + carboplatin as neoadjuvant therapy for resectable esophageal small cell carcinoma (Phase II, single-arm)
ChiCTR2300078679Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in small cell carcinoma of the esophagus (SCEC), sponsored by West China Hospital of Sichuan University. Primary endpoint: One-year overall survival rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on ChiCTR2300078679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078679.